ARCT - Arcturus Therapeutics Holdings Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Ltd is a biotechnology company developing novel RNA medicines. The company develops novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases.
IPO Date: May 22, 2013
Sector: Healthcare
Industry: Biotech
Market Cap: $362.82M
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.02 | 4.13%
Avg Daily Range (30 D): $0.77 | 5.17%
Avg Daily Range (90 D): $0.44 | 4.05%
Institutional Daily Volume
Avg Daily Volume: .42M
Avg Daily Volume (30 D): .91M
Avg Daily Volume (90 D): .71M
Trade Size
Avg Trade Size (Sh.): 65
Avg Trade Size (Sh.) (30 D): 67
Avg Trade Size (Sh.) (90 D): 63
Institutional Trades
Total Institutional Trades: 2,237
Avg Institutional Trade: $1.96M
Avg Institutional Trade (30 D): $1.07M
Avg Institutional Trade (90 D): $1.09M
Avg Institutional Trade Volume: .07M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.25M
Avg Closing Trade (30 D): $1.17M
Avg Closing Trade (90 D): $1.18M
Avg Closing Volume: 79.73K
 
News
Aug 26, 2026 @ 1:46 PM
mRNA Therapeutics Market Outlook Report 2026-2035 ...
Source: Researchandmarkets.Com
Mar 23, 2026 @ 11:07 AM
These Are the Only 3 Stocks That Cathie Wood Bough...
Source: Rick Munarriz
Oct 23, 2025 @ 1:15 PM
Cathie Wood Goes Shopping: 3 Stocks She Just Bough...
Source: Rick Munarriz
Sep 29, 2025 @ 5:35 PM
10 Health Care Stocks With Whale Alerts In Today's...
Source: Benzinga Staff Writer
Aug 5, 2025 @ 10:00 AM
Lipid Nanoparticles Market Industry Trends, Key Gr...
Source: Researchandmarkets.Com
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-3.33 $-.84 $-.95
Diluted EPS $-3.33 $-.84 $-.95
Revenue $29.37M $2.96M $2.06M
Gross Profit
Net Income / Loss $-93.28M $-23.79M $-26.96M
Operating Income / Loss $-102.3M $-25.55M $-28.93M
Cost of Revenue
Net Cash Flow $-59.84M $-19.89M $-19.39M
PE Ratio    
Splits
Nov 16, 2017 1:7